Therefore, the combination of drugs targeting the pro-oncogenic role of EZH2 in tumoral cells and its role promoting an immunosuppressive TME, with immunotherapy, could have a synergistic effect, improving the therapeutic responses of some types of cancer. This evidence concerns the gene EZH2 and cancer.